The combination of anti-PD-1 (INCMGA0012) and GITR mAb (INCAGN01876) was tested in a phase 2 trial (NCT04225039), with and without radiosurgery in patients with recurrent glioblastoma. The gene discussed is TNFRSF18; the disease is glioblastoma.